AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02804854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrophil Activation Probe (NAP)
Description: Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
Study NCT06119633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate tissue expander and lipofilling after mastectomy
Description: Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
Study NCT04019938 — intervention group
Intervention type: RADIATION
Intervention: Dual-energy X-ray absorptiometry
Description: Cystatin C is measured as a part of routine investigation at the time of admission.
Study NCT02955511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blade MAC size 3
Description: Patient will be intubated using the DL- Blade MAC size 3
Study NCT02955511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blade MAC size 3.5
Description: Patient will be intubated using the DL- Blade MAC size 3.5
Study NCT02955511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inscope Blade size 3.5
Description: Patient will be intubated using the Inscope Blade size 3.5
Study NCT03913741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
Study NCT01158131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance after Baby Lifestyle Intervention Program
Description: Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
Study NCT02715921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exercise
Study NCT04721054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)
Description: patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Study NCT04721054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia effect on heart rate in Laparoscopic Cholecystectomy
Description: patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Study NCT02698072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
Study NCT02698072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: 20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
Study NCT02698072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling needle AGUPUNT®
Study NCT02698072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham dry needling
Description: Sham dry needling DONGBANG-ACUPRIME®
Study NCT01566045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Needle TRUS Needle biopsy (Transrectal ultrasound)
Description: Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
Study NCT01566045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Needle MRI/US image fusion guided needle biopsy
Description: Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
Study NCT01953081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8954
Study NCT01953081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Study NCT03819660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate 10 MG Oral Tablet
Description: Oral tablets
Study NCT03835533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214 (Cohort A)
Description: NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
Study NCT03835533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Cohort A, B and C)
Description: Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
Study NCT03835533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) (Cohort B)
Description: Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
Study NCT03835533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301 (Cohort B and C)
Description: CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
Study NCT03835533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC (Cohort B)
Description: Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
Study NCT03835533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-5151 (Cohort C)
Description: INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
Study NCT03835533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000
Description: Electroporation device
Study NCT00735046 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive behavioral therapy for early Alzheimer's disease
Description: 12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
Study NCT00735046 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Patients and proxies who are assigned to treatment as usual
Study NCT00507455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Solifenacin succinate tablets
Study NCT00507455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
Study NCT02936739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with prosthetic disc replacement / ESP.
Description: Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
Study NCT00507455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to solifenacin
Study NCT00507455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tamsulosin
Study NCT02182115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiseptic bundle
Description: 1. Chlorhexidine gluconate liquid soap for bathing daily.~2. Chlorhexidine gluconate mouthrinse to use twice daily.~3. Nasal mupirocin to apply twice daily.
Study NCT02182115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
Study NCT03710967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the primary motor cortex
Study NCT03710967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the primary motor cortex
Study NCT03123393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets
Study NCT03649932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline
Description: L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere.
Study NCT02435537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine (Precedex)
Description: intrathecal administration
Study NCT02435537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intrathecal 10 mg bupivacaine
Study NCT02936739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy with prosthetic disc replacement / Rotaio.
Description: Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
Study NCT04652050 — intervention group
Intervention type: DRUG
Intervention: Tolsura
Description: Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
Study NCT02946788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: BPX-01 1 or 2% topical gel will be applied to face once daily
Study NCT00586430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: single 2 mg dose of lorazepam
Study NCT00586430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo
Study NCT02089984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based CBT Training
Study NCT02832453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
Study NCT02832453 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
Study NCT02832453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
Study NCT02832453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
Study NCT02832453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional continous training
Description: The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
Study NCT02965599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3117391
Description: GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
Study NCT02965599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a white, opaque, gelatin capsule.
Study NCT01550783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Papanicolaou Test
Description: Undergo standard of care Pap test screening
Study NCT01550783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo home-based HPV screening
Study NCT01550783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01550783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening Method
Description: Undergo standard of care Pap test screening
Study NCT01550783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening Method
Description: Undergo home-based HPV screening
Study NCT03254524 — intervention group
Intervention type: OTHER
Intervention: Statewide Planning and Research Cooperative System Database
Description: The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
Study NCT03171389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
Study NCT04179773 — intervention group
Intervention type: OTHER
Intervention: Current care study
Description: Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject.
Study NCT03756181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five-week MSC program (MSC5wk)
Description: This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
Study NCT03756181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Five-week MSC program (MSC5wk)
Description: This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
Study NCT04530032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic/modified Atkins diet
Description: ketogenic/modified Atkins diet use
Study NCT04530032 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard diet
Description: standard (normal) diet use
Study NCT03339986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction or Replacement
Study NCT04506866 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Micro
Description: Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
Study NCT01898338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin 2gr/6h iv
Study NCT01898338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin 2gr/6h iv
Study NCT01898338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 10mg/kg/24h iv
Study NCT01116570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training during 24 weeks
Study NCT01116570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study NCT01412008 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Botox (botulinum toxin)
Description: A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
Study NCT03550313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study NCT03891433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Carbapenems group intervention.
Study NCT02435537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intrathecal 0.5mg morphine
Study NCT05930054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: skeletal anchorage and rapid palatal expansion
Description: Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
Study NCT00810667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054
Description: twice daily oral dose (60 mg BID: total dose 120 mg/day)
Study NCT00810667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily oral dose
Study NCT03578432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03578432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03578432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00204698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex
Description: 20 mg of aciphex taken twice daily
Study NCT01438892 — intervention group
Intervention type: DRUG
Intervention: tDMARDs
Description: Traditional DMARDs for RA
Study NCT01438892 — intervention group
Intervention type: DRUG
Intervention: biodmards
Description: Biologic DMARDs